Cethromycin Salt Polymorphs for Faster Antimicrobial Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for bacterial and protozoan infections, including malaria and inflammatory diseases, lack effective compounds that inhibit protein synthesis and provide rapid therapeutic responses.
Innovation Solution
Development of novel cethromycin salts and polymorphs, particularly those with acetic acid, phosphoric acid, or hydrochloric acid, which inhibit bacterial and protozoan protein synthesis, offering therapeutic options for diseases such as malaria, Toxoplasmosis, and inflammatory diseases like pelvic inflammatory disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing treatments for bacterial and protozoan infections are used, then the infections can be treated, but the therapeutic response is not rapid enough and efficacy is insufficient
Solution Approach 1:
The patent modifies the chemical parameters of cethromycin by creating multiple salt forms (phosphate, acetate, chloride) and polymorphs, which changes the physical and chemical properties to enhance absorption, distribution, and microbial killing speed, thereby achieving rapid therapeutic response with high efficacy
Solution Approach 2:
The patent creates composite structures by combining cethromycin with different counterions (phosphate, acetate, chloride) to form salt compounds, and by generating multiple crystal polymorphs, resulting in materials with enhanced biological activity and rapid therapeutic effects
2Speed
If cethromycin salts and polymorphs are developed to inhibit protein synthesis, then microbial killing speed increases, but the complexity of the compound structure increases
Solution Approach 1:
The patent changes the chemical parameters of cethromycin by forming salts with different acids (phosphoric, acetic, hydrochloric) and creating polymorphs, which modifies physical properties like solubility and permeability to enhance killing speed without fundamentally altering the core macrolide structure
Solution Approach 2:
The patent separates the complex task of enhancing microbial killing into multiple manageable approaches: creating different salt forms, generating polymorphs, and optimizing physical properties, allowing systematic improvement of killing speed while managing structural complexity
3Reliability
If novel cethromycin salts and polymorphs are synthesized, then therapeutic efficacy is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent modifies manufacturing by changing the form of cethromycin into different salt forms and polymorphs, which can be achieved through controlled crystallization and salt formation processes, enhancing therapeutic efficacy while maintaining feasibility of manufacturing
Solution Approach 2:
The patent performs preliminary characterization and optimization of cethromycin salts and polymorphs before full-scale manufacturing, identifying the most promising forms with highest efficacy and easiest synthesis pathways to guide subsequent production
Data Source
AI summary
Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.